K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$2.14
Prev. Close
$1.55
Prev. Day's Range
$1.53 - $2.30
52W Range
$1.12 - $29.34
Trading Volume
6.385M
MC
$17.642M
P/E Ratio
--
EPS
$-10.56
Company Overview
NASDAQ
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company is headquartered in Lexington, Massachusetts.
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters3 VAN DE GRAAFF DRIVE, BURLINGTON, MA, UNITED STATES, 01803
GUTS operates in the [specific sector and industry], focusing on [core business activity]. The company is known for its [main revenue drivers], which include [key products or services]. Investors should review the company's core strengths and market position when evaluating its stock.
GUTS primarily earns revenue through [describe main revenue drivers]. These include [specific services, manufacturing, or other operations]. The company's financial performance is largely dependent on [sector trends or market demands].
GUTS belongs to the [specific sector and industry]. This sector is characterized by [major trends, challenges, or growth potential]. Investors should be aware of how GUTS competes within this industry and how macroeconomic factors might impact its performance.
Yes, GUTS pays dividends to its shareholders, reflecting its commitment to returning value. The dividend rate and yield depend on the company’s financial health and market conditions. Investors should monitor dividend announcements for updates on payouts.
Investing in GUTS involves risks such as [specific risks tied to the company or sector, e.g., economic sensitivity, regulatory challenges]. While the company has growth potential, external factors like [mention risks like competition or market volatility] can impact its stock performance.
GUTS competes with companies like [name major relevant competitors]. These competitors operate in the same industry and may impact GUTS’s market share. Investors often compare financial metrics and strategic positioning within this competitive landscape.
GUTS’s valuation metrics, such as price-to-earnings (P/E) ratio and price-to-book (P/B) ratio, should be compared to peers in its industry. Differences in valuation often reflect growth prospects, risks, or unique operational characteristics of the business.
Opportunities for GUTS include [specific growth factors, such as market expansion, product innovations, or strategic partnerships]. However, investors should also consider potential risks, such as [industry challenges or operational hurdles] that might impact its ability to capitalize on these opportunities.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.